Clinical Trials Logo

Clinical Trial Summary

PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04866680
Study type Interventional
Source Institut de Cancérologie de Lorraine
Contact MERLIN JEAN-LOUIS, PharmD, PhD
Phone 33 3 83 65 60 62
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date June 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Active, not recruiting NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Recruiting NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Recruiting NCT02854488 - Yervoy Pregnancy Surveillance Study N/A
Suspended NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00706238 - MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma Phase 2
Recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma Phase 1/Phase 2
Active, not recruiting NCT03747744 - Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) Phase 1
Recruiting NCT03683550 - Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma N/A
Recruiting NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01667419 - A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Phase 3
Recruiting NCT04096638 - Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT01118832 - Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Terminated NCT02796352 - A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Phase 2